Evidence map›Paper›PMID 38732041›Full record

ArticleInternational journal of molecular sciences2024

Evaluating the Diagnostic Potential of Combined Salivary and Skin Biomarkers in Parkinson's Disease.

Matteo Costanzo, Eleonora Galosi, Maria Ilenia De Bartolo, Gaetano Gallo, Giorgio Leodori, Daniele Belvisi, Antonella Conte, Giovanni Fabbrini, Andrea Truini, Alfredo Berardelli and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matteo CostanzoDepartment of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.ORCID 0000-0002-4369-014X
Eleonora GalosiDepartment of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.
Maria Ilenia De BartoloIRCCS Neuromed, Via Atinense 18, 86077 Isernia, Italy.ORCID 0000-0002-8747-9805
Gaetano GalloUnità Operativa Complessa Neurologia, Ospedali Riuniti Padova Sud, Via Albere 30, 35043 Padova, Italy.ORCID 0000-0003-1066-4671
Giorgio LeodoriDepartment of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.ORCID 0000-0002-6631-6740
Daniele BelvisiDepartment of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.
Antonella ConteDepartment of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.ORCID 0000-0002-6338-2961
Giovanni FabbriniDepartment of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.
Andrea TruiniDepartment of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.
Alfredo BerardelliDepartment of Human Neuroscience, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy.
Giorgio VivacquaDepartment of Experimental Morphology and Microscopy-Integrated Research Center (PRAAB), Campus Biomedico University of Rome, 00128 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligomeric alpha-synuclein (α-syn) in saliva and phosphorylated α-syn deposits in the skin have emerged as promising diagnostic biomarkers for Parkinson's disease (PD). This study aimed to assess and compare the diagnostic value of these biomarkers in discriminating between 38 PD patients and 24 healthy subjects (HSs) using easily accessible biological samples. Additionally, the study sought to determine the diagnostic potential of combining these biomarkers and to explore their correlations with clinical features. Salivary oligomeric α-syn levels were quantified using competitive ELISA, while skin biopsies were analyzed through immunofluorescence to detect phosphorylated α-syn at Ser129 (p-S129). Both biomarkers individually were accurate in discriminating PD patients from HSs, with a modest agreement between them. The combined positivity of salivary α-syn oligomers and skin p-S129 aggregates differentiated PD patients from HSs with an excellent discriminative ability with an AUC of 0.9095. The modest agreement observed between salivary and skin biomarkers individually suggests that they may reflect different aspects of PD pathology, thus providing complementary information when combined. This study's results highlight the potential of utilizing a multimodal biomarker approach to enhance diagnostic accuracy in PD.

Indexed as

alpha-SynucleinBiomarkersParkinson DiseaseSalivaSkinAgedCase-Control StudiesFemaleHumansMaleMiddle AgedPhosphorylationalpha-SynucleinBiomarkersSNCA protein, humanalpha-synucleinbiomarkersParkinson’s diseasesynucleinopathies

Identifiers

PMID38732041
PMCPMC11084721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.